- Home
- SIGIP vs GALT Comparison
SIGIP vs GALT Comparison
Compare SIGIP & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGIP
- GALT
- Stock Information
- Founded
- SIGIP N/A
- GALT 2000
- Country
- SIGIP United States
- GALT United States
- Employees
- SIGIP 2800
- GALT N/A
- Industry
- SIGIP Property-Casualty Insurers
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- SIGIP Finance
- GALT Health Care
- Exchange
- SIGIP Nasdaq
- GALT Nasdaq
- Market Cap
- SIGIP N/A
- GALT 86.0M
- IPO Year
- SIGIP N/A
- GALT N/A
- Fundamental
- Price
- SIGIP $17.23
- GALT $1.40
- Analyst Decision
- SIGIP
- GALT Hold
- Analyst Count
- SIGIP 0
- GALT 1
- Target Price
- SIGIP N/A
- GALT N/A
- AVG Volume (30 Days)
- SIGIP N/A
- GALT 177.8K
- Earning Date
- SIGIP N/A
- GALT 05-19-2025
- Dividend Yield
- SIGIP N/A
- GALT N/A
- EPS Growth
- SIGIP N/A
- GALT N/A
- EPS
- SIGIP N/A
- GALT N/A
- Revenue
- SIGIP N/A
- GALT N/A
- Revenue This Year
- SIGIP N/A
- GALT N/A
- Revenue Next Year
- SIGIP N/A
- GALT N/A
- P/E Ratio
- SIGIP N/A
- GALT N/A
- Revenue Growth
- SIGIP N/A
- GALT N/A
- 52 Week Low
- SIGIP N/A
- GALT $0.73
- 52 Week High
- SIGIP N/A
- GALT $3.41
- Technical
- Relative Strength Index (RSI)
- SIGIP 43.17
- GALT 50.78
- Support Level
- SIGIP $17.06
- GALT $1.26
- Resistance Level
- SIGIP $17.40
- GALT $1.42
- Average True Range (ATR)
- SIGIP 0.19
- GALT 0.12
- MACD
- SIGIP 0.03
- GALT 0.02
- Stochastic Oscillator
- SIGIP 30.14
- GALT 42.61
About SIGIP Selective Insurance Group Inc. Depositary Shares each representing a 1/1000th interest in a share of 4.60% Non-Cumulative Preferred Stock Series B
Selective Insurance Group Inc is a regional property-casualty insurer based in New Jersey, with its operations focused in the New York metropolitan area. The Company has four operating segments: Standard Commercial Lines, Standard Personal Lines, E&S Lines, Investments. Majority of revenue is gained from Standard Personal Lines. Currently company has it's revenues from States of USA and Columbia.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.